ReviewEuropean journal of medical research2025
Pathogenesis and clinical management of chronic multilobar segmental bronchial stenosis: a literature review.
Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hypoxic Pulmonary Hypertension: Molecular Mechanisms and Clinical Research Advances.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Chronic multilobar segmental bronchial stenosis (CMBS) represents a chronic airway inflammatory disorder characterized by fibrotic narrowing of multiple lobar and segmental bronchi. Its pathogenesis is closely associated with chronic exposure to biomass smoke and tuberculosis infection. CMBS demonstrates high morbidity and poor prognosis, representing a condition of growing clinical significance. However, its underlying pathophysiological mechanisms remain incompletely elucidated. Epidemiological studies reveal a notably higher disease prevalence in developing countries, with particular susceptibility observed in female populations and tuberculosis-endemic cohorts. The pathogenic cascade involves an "inflammatory-oxidative damage-fibrosis" axis, wherein biomass smoke induces airway remodeling through epigenetic reprogramming and mitochondrial dysfunction. Characteristic clinical manifestations include obstructive ventilatory impairment accompanied by pulmonary hypertension. Current therapeutic strategies predominantly rely on bronchodilators and antitubercular agents, yet fail to reverse established fibrotic lesions. Future directions necessitate coordinated public health interventions for early disease detection, deeper exploration of molecular mechanisms, and the development of targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.